Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis
Source abstract
Abstract
Sepsis, a condition caused by severe infections, affects more than 30 million people worldwide every year and remains the leading cause of death in hospitals1,2. Moreover, antimicrobial resistance has become an additional challenge in the treatment of sepsis3, and thus, alternative therapeutic approaches are urgently needed2,3. Here, we show that adoptive transfer of macrophages containing antimicrobial peptides linked to cathepsin B in the lysosomes (MACs) can be applied for the treatment of multidrug-resistant bacteria-induced sepsis in mice with immunosuppression. The MACs are constructed by transfection of vitamin C lipid nanoparticles that deliver antimicrobial peptide and cathepsin B (AMP-CatB) mRNA. The vitamin C lipid nanoparticles allow the specific accumulation of AMP-CatB in macrophage lysosomes, which is the key location for bactericidal activities. Our results demonstrate that adoptive MAC transfer leads to the elimination of multidrug-resistant bacteria, including Staphylococcus aureus and Escherichia coli, leading to the complete recovery of immunocompromised septic mice. Our work provides an alternative strategy for overcoming multidrug-resistant bacteria-induced sepsis and opens up possibilities for the development of nanoparticle-enabled cell therapy for infectious diseases.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Antimicrobial Peptides and Activities · Immune Response and Inflammation · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (28)
Show source-provided references
1. Reinhart, K. et al. Recognizing sepsis as a global health priority—a WHO resolution. N. Engl. J. Med. 377, 414–417 (2017).10.1056/NEJMp1707170 ↗
2. van der Poll, T. Immunotherapy of sepsis. Lancet Infect. Dis. 1, 165–174 (2001).10.1016/S1473-3099(01)00093-7 ↗
3. Huttunen, R. & Aittoniemi, J. New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis. J. Infect. 63, 407–419 (2011).10.1016/j.jinf.2011.08.004 ↗
4. Hotchkiss, R. S. & Karl, I. E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138–150 (2003).10.1056/NEJMra021333 ↗
5. Otto, G. P. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit. Care 15, R183 (2011).10.1186/cc10332 ↗
6. Hotchkiss, R. S., Monneret, G. & Payen, D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 13, 260–268 (2013).10.1016/S1473-3099(13)70001-X ↗
7. Czermak, B. J. et al. Protective effects of C5a blockade in sepsis. Nat. Med. 5, 788–792 (1999).10.1038/10512 ↗
8. Ward, P. A. & Fattahi, F. New strategies for treatment of infectious sepsis. J. Leukoc. Biol. 106, 187–192 (2019).10.1002/JLB.4MIR1118-425R ↗
9. Huang, X. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl Acad. Sci. USA 106, 6303–6308 (2009).10.1073/pnas.0809422106 ↗
10. Docke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3, 678–681 (1997).10.1038/nm0697-678 ↗
11. Presneill, J. J., Harris, T., Stewart, A. G., Cade, J. F. & Wilson, J. W. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir. Crit. Care Med. 166, 138–143 (2002).10.1164/rccm.2009005 ↗
12. Galbraith, N., Walker, S., Galandiuk, S., Gardner, S. & Polk, H. C. Jr The significance and challenges of monocyte impairment: for the ill patient and the surgeon. Surg. Infect. 17, 303–312 (2016).10.1089/sur.2015.245 ↗
13. Bo, L., Wang, F., Zhu, J., Li, J. & Deng, X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit. Care 15, R58 (2011).10.1186/cc10031 ↗
14. Foster, T. J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3, 948–958 (2005).10.1038/nrmicro1289 ↗
15. Garzoni, C. & Kelley, W. L. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol. 17, 59–65 (2009).10.1016/j.tim.2008.11.005 ↗
16. Lewis, A. J., Richards, A. C. & Mulvey, M. A. Invasion of host cells and tissues by uropathogenic bacteria. Microbiol. Spectr. 4, UTI-0026-2016 (2016).10.1128/microbiolspec.UTI-0026-2016 ↗
17. Pauwels, A. M., Trost, M., Beyaert, R. & Hoffmann, E. Patterns, receptors, and signals: regulation of phagosome maturation. Trends Immunol. 38, 407–422 (2017).10.1016/j.it.2017.03.006 ↗
18. Giles, F. J., Redman, R., Yazji, S. & Bellm, L. Iseganan HCl: a novel antimicrobial agent. Expert Opin. Investig. Drugs 11, 1161–1170 (2002).10.1517/13543784.11.8.1161 ↗
19. Linke, M., Herzog, V. & Brix, K. Trafficking of lysosomal cathepsin B-green fluorescent protein to the surface of thyroid epithelial cells involves the endosomal/lysosomal compartment. J. Cell Sci. 115, 4877–4889 (2002).10.1242/jcs.00184 ↗
20. Vasey, P. A. et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents–drug-polymer conjugates. Clin. Cancer Res. 5, 83–94 (1999).
21. Frimodt-Møller, N., Knudsen, J. & Espersen, F. in Handbook of Animal Models of Infection 127–136 (1999).10.1016/B978-012775390-4/50153-6 ↗
22. McVicker, G. et al. Clonal expansion during Staphylococcus aureus infection dynamics reveals the effect of antibiotic intervention. PLoS Pathog. 10, e1003959 (2014).10.1371/journal.ppat.1003959 ↗
23. Crow, D. Could iPSCs enable “off-the-shelf” cell therapy? Cell 177, 1667–1669 (2019).10.1016/j.cell.2019.05.043 ↗
24. Ying, W., Cheruku, P. S., Bazer, F. W., Safe, S. H. & Zhou, B. Investigation of macrophage polarization using bone marrow derived macrophages. J. Vis. Exp. 76, e50323 (2013).
25. Zhang, C. et al. Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. Nano Res. 12, 855–861 (2019).10.1007/s12274-019-2308-9 ↗
26. Li, B. et al. An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo. Nano Lett. 15, 8099–8107 (2015).10.1021/acs.nanolett.5b03528 ↗
27. Su, X., Fricke, J., Kavanagh, D. G. & Irvine, D. J. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol. Pharm. 8, 774–787 (2011).10.1021/mp100390w ↗
28. Zhang, L. et al. High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc. Natl Acad. Sci. USA 104, 4606–4611 (2007).10.1073/pnas.0609370104 ↗